Damage to primary sensory neurons may result in chronic neuropathic pain. Patients suffering from such pain comprise an important part of the workload of pain relief clinics. The pathopysiology of neuropathic pain is poorly understood and, as a result, treatment is often unsuccessful. Many different types of mononeuropathy and potyneuropathy may lead to pain and these will be reviewed, together with the clinical features of neuropathic pain and the abnormal accompanying signs. An attempt will be made to relate symptoms and signs to altered physiology, evidence for which derives mainly from experimental studies. This topic is further discussed in this symposium by Koltzenberg. Attention will be drawn to the evidence which indicates that a peripheral lesion may initiate abnormal changes peripherally and centrally, particularly at spinal cord level. Treatment of neuropathic pain involves the use of local and systemic measures. Local measures may include various forms of counterstimulation, the use of topical local anaesthetic and capsaicin and local anaesthetic blocks, and regional sympathetic blockade in patients with mononeuropathies. Clinical evidence pointing to the involvement of sympathetic efferent activity in peripheral neuropathic pain mid the results of sympathetic block will be discussed. Numerous classes of drug have been advocated for the treatment of peripheral neuropathic pain, though there have been relatively few satisfactorily designed controlled trials. The use of systemic drug therapy will be evaluated critically, with particular emphasis on antidepressants, anticonvulsants and opiates. The possible role of N-methyl-D-aspartic acid (NMDA) receptor blocking drugs will be considered. Finally, the evidence indicating that early treatment may be important in preventing the establishment of chronic neuropathic pain, and the possible place of pre-emptive analgesia in certain situations will be discussed.
NEUROPHYSIOLOGICAL INVESTIGATIONS OF NEUROPATHIC PAIN MECHANISMS. M Koltzenburg, Wurzburg, Germany
Ongoing pain and hyperalgesia are common symptoms in neuropathic conditions. Individual patients often present with a variety of enigmatic symptoms, the basis of which is only now becoming understood. It has recently been recognised that chronic neuropathic pain has many features in common with acute experimental pain that can be studied in normal volunteers following application of irritant chemicals notably capsaicin. Surprisingly, these investigations showed that a particular symptom such as touch-evoked pain is mediated by very similar, if not identical, neural mechanisms in both the experimental or neuropathic condition, and that each particular pain mechanism involves distinct peripheral and central neural events. Knowledge about these events becomes important if we are to target them for therapeutic interventions. Direct microneurographic recordings from peripheral nerves in conscious humans have determined that the magnitude of the ongoing stimulus-independent pain is signalled by the discharge intensity of nociceptive afferents in acute chemogenic and chronic neuropathic pain. Following nerve damage, the increased excitability of nociceptors is probably caused by changes of membrane properties. Detailed psychophysical investigations have identified at least four different mechanisms that can contribute to the hypersensitivity to mechanical stimuli. For example, touch-evoked pain (allodynia) is signalled by sensitive mechanoreceptors with large myelinated fibres that nmmally encode tactile sensations. There is consensus that this functional switch involves a plasticity of the central nervous system, commonly known as central sensitisation, that is precipitated and maintained by an ongoing discharge of peripheral nociceptors. Several studies suggest that NMDA receptors may be critically important for these central processes. Moreover, hyperalgesia to pin-prick stimuli is encoded by normal mechanosensitive nociceptors that impinge on a sensitised central nervous system. In contrast, hyperalgesia to firm pressure or impact stinmli is probably the consequence of peripheral sensitisation, namely an increased responsiveness of nociceptors to these stimuli. Likewise, hyperalgesia to heat, which is prominent after tissue injury but relatively infrequent in neuropathy, is mediated by sensitised nociceptors and this has been directly proven with microneurographic recordings. At present the mechanisms of cold hyperalgesia are not completely understood, but might involve central disinhibitation of nociceptive activity by specific cold receptor inputs. Some neuropathic pain states appear to be maintained by the sympathetic nervous system, probably because nociceptors acquire a novel sensitivity to catecholamines following nerve damage.
PATHOPHYSIOLOGY OF REFLEX SYMPATHETIC DYSTROPHY.

W Janig, KieI, Germany
The sympathetic nervous system is efferent and organized in a target organ specific way. This is the basis for the precise regulation of body functions under healthy conditions. There is evidence that this system may become involved in the generation of pain as a consequence of trauma, particularly to the limbs, either with or without obvious nerve lesions. This group of disorders is known variously as ,,reflex sympathetic dystrophy" (RSD), ,,sympathetically maintained pain" (SMP) etc. It consists of pain, abnormal regulation of blood flow and sweating, abnormalities in the motor system and trophic changes. Sympathetic blocks may cure the disease. How is the (efferent) sympathetic nervous system involved in the generation of these (afferent) pain syndromes? The putative pathophysiological mechanisms may operate at the level of the effector organ, in the peripheral afferent and sympathetic neurons, in the spinal cord and in the supraspinal ,,control centres". Nociceptive neurons with C-and A-fibres become sensitized and are probably the most important peripheral sensory component in initiating and maintaining the central ,,pain state". Neurons of the central nociceptive pathway (notably in the dorsal horn) also become sensitized, leading to continuous pain, hyperalgesia and allodynia. The latter probably only occurs in a minority of RSD patients, although it may be very important in SMP patients. Sympathetic activity maintains activity in the nociceptive A-and C-fibres. Several ways of direct and indirect coupling between the sympathetic outflow and the primary afferent neurons are possible and these may vary between types of RSD/SMP: a) Chemical (noradrenergic) coupling on the periphery (at the lesion site) and in the dorsal root ganglion or even along the lesioned nerve, b) Indirect coupling via the micromilieu of the target tissue, c) Changes in the neurovascular transmission after nerve lesions contributing to the abnormal regulation of blood flow and therefore to changes of the micromilieu of the afferent fibre terminals. Sensitization of the central nociceptive pathway probably generates abnormal behavionr of both the sympathetic nervous outflow and skeleto-motor outflow. Reflexes in the sympathetic neurons to the traumatized extremity may change without any overall increase or even a decrease in activity. RSD/SMP is a group of complex disorders with sensory, sympathetic, and skeleto-motor components. In the future, it may be possible to characterize each of these disorders by its own clinical phenomenology and corresponding pathology.
CENTRAL PAIN. G D Schott, London, UK
Central pain is pain that arises from disease or dysfunction of the central nervous system. Stroke, multiple sclerosis, and spinal cord injury are the three commonest causes, and it is now apparent that central pain occurs more frequently than had been realised. The concept dates from 1906, when Dejerine and Roussy described ,,le syndrome thalamique", in which a vascular lesion affecting the thalamus was associated with pain. Modem imaging techniques, however, have confirmed that pain can occur when strokes involve areas other than the thalamus, and the term thalamic syndrome is being replaced by ,,central post-stroke pain". Pain may be severe, have a delayed onset after the initiating insult, and can be both spontaneous and evoked. The pain nearly always occurs in areas of impaired sensation, although the impairment is sometimes very slight and occasionally affects pain and temperature appreciation selectively. Somatosensory cerebral potentials evoked by electrical and laser stimulation have confirmed that function of large-diameter fibres may be intact whereas that of small-diameter fibres may be impaired in central post-stroke pain. Treatment is frequently unsatisfactory, its efficacy unpredictable, and cure is rare. Most studies are uncontrolled, anecdotal, comprise few patients, and often report little follow up. Tricyclic antidepressants remain the main drug option. Benefit from anticonvulsants, calcium-channel blockers, phenothiazines, and numerous other drugs, sometimes in combination, has not been established. Benzodiazepines and naloxone are ineffective. The role of antiarrhythmic drugs such as lignocaine and mexiletine remains to be clarified. The use of opiates is a controversial and cmTently unresolved issue. New drug approaches include N-methyl-D-aspartate (NMDA) $4 receptor antagonists such as ketamine, and intrathecal baclofen. Nonpharmacological treatments have included both ablative methods and, often preferred because of comparative safety, various stimulation procedures of which motor cortex stimulation is the most recent technique. The psychologist has an important contribution in management of the pain and its psychological sequelae. Possible underlying mechanisms include abnormal excitation of sensory pathways, (perhaps secondary to) damage to inhibitory pathways, and the effects of neural plasticity. Within the brain, hyperactivity of deafferented thalamic neurons may be relevant, and metabolic changes in the thalamus and cortex in central pain are currently being investigated. Ceutral physiological and biochemical changes also result from lesions of the periphery, and the effects of peripheral deafferentation on the generation of central pain and thus the nosology of central pain itself remain to be clarified.
Symposium 4: Animal Models of Neurological Diseases
ANIMAL MODELS OF PARKINSON'S DISEASE (PD). Josd A Obeso, Pamplona, Spain
There are three major animal models of parkinsonism: 1) The reserpinized rat. 2) A unilateral lesion of the dopaminergic nigrostriatal pathway by 6-hydroxydopamine in the rat. 3) Unilateral or bilateral lesion of the dopaminergic neurons in the substantia nigra pars compacta produced by by l-methyl-4-phenyl-l,2,3,6qetrahydropyridine (MPTP). 6-hydroxydopamine injection in the rat induces massive striatal depletion of dopamine, with acute onset and eventually neuronal degeneration in the substantia nigra compacta by retrogade transport of the neurotoxin. Spontaneous rotatory activity may occur, but most frequently administration of dopaminergic drugs is required to induce this motor manifestation. Typically, dopamine agonists like apomorphine provoke rotatory activity contralateral (to the lesion side) and drugs enhancing dopamine release, like amphetamine, produce rotations ipsilateral to the lesion. The major advantages of the rat models are the easiness of handling, the relatively low cost and therefore the possibility of using a sufficiently high number of animals per experiment.The major drawback is that rats with depletion or lesions of the dopaminergic system do not show any feature comparable to those of PD and the nature of the lesion falls distant from the chronic changes which accompany neuronal degeneration in PD. Finally, the rat brain is not organized in a fashion which mimics the human brain. The monkey MPTP model is an excellent behavioral and anatomochemical model of PD.The most common species employed in experimental neurology are the marmoset and the macaque.The distribution of the lesion, the biochemical features, the clinical manifestations and response to therapy are all extremely close to what is seen in patients with PD. MPTP may be given by intravenous or subcutaneous administration to induce bilateral parkinsonism and intracarotid to achieve mainly unilateral motor symptoms. Usually several doses have to be given in order to obtain a stable parkinsonian state. The capacity for recovery of the monkey is remarkable, so that more than 90% dopamine depletion is required to assure permanent parkinsonism. The MPTP model has been successfully used to evaluate new antiparkinsonian drugs, the mechanisms of dyskinesias, the effect of striatal transplants and subthalamatomy. The major limitation of this model resides in the high cost and relative scarceness of animals, requirement of special housing facilities, and the fact that precise evaluation of the motor state depends upon sophisticated technology.
ANIMAL MODELS OF HUMAN PRION DISEASE. J Collinge, London, UK
Prion diseases are neurodegenerative conditions which are transmissible to experimental animals following inoculation or dietary exposure. The transmissible agent or prion consists principally of a modified form of a host encoded glycoprotein, the prion protein (PrP). This disease related isoform, PrP sc, differs from the cellular isoform, PrP c, by a post-translational modification which appears to involve a conformational change. Human prion diseases occur in inherited, sporadic and acquired forms. The inherited forms are caused by coding mutations in the PrP gene; genetic susceptibility to acquired and sporadic disease is determined by a common protein polymorphism (at residue 129), individuals homozygous with respect to this polymorphism being at higher risk. The current model of prion propagation is that PrP s~ acts as a template which promotes the conversion of PrP c to PrP sc. This process occurs most efficiently when the interacting species are of identical primary structure.
We are developing a transgenic model of human prion disease. Recently, we have transmitted Creutzfeldt-Jakob disease (CJD) to mice overexpressing wild-type human PrP and have demonstrated, using species specific monoclonals, that these mice produce human PrP s~ Such mice now allow experimental study of the species barrier limiting transmission of animal prion diseases to humans and we are studying their susceptibility to both bovine spongiform encephalopathy and scrapie. In addition, we have been studying mice in which the PrP gene has been inactivated by gene targeting. The initial report that such PrP null mice, which do not express PrP, had no detectable phenotype argued that PrP s~ accumulation, rather than PrP c loss of function, was the cause of neuronal damage in prion diseases. However, we have demonstrated abnormalities of inhibitory neurotransmission in PrP null mice that are relevant to the epileptic like discharges seen in the electroencephalogram in CJD and in scrapie-infected mice, reinstating the possibility that neurodegeneration is due, at least in part, to loss of function of PrP. CJD is typically associated with myoclonus and, in about 10% of cases, with generalised seizures. It is therefore possible that the abnormalities seen in PrP null mice represent a partially compensated form of prion disease. Loss of PrP c in an adult nervous system may have far more severe effects than in a developing one, where compensatory adaptation can be expected at many levels during neurodevelopment. Such a mechanism for priori neurodegeneration is more consistent with the lack of correlation between neuropathological features (including the amount of PrP sc that is deposited in the brain as amyloid plaques) and clinical severity in these diseases. We have now demonstrated rescue of the PrP null phenotype by transgenes expressing human PrP, confirming the specificity of the phenotype for toss of PrP. Furthemlore, the ability of human PrP to compensate for loss of routine PrP will allow direct study of the functional consequences of the 18 human PrP mutations which cause the inherited prion diseases.
TRANSGENIC AND KNOCK-OUT MODELS OF NEURODEGEN-ERATIVE DISEASES. Adriano Aguzzi, Ziirich, Switzerland
Experiments based on the modification of the mammalian germ line genome are changing our understanding of the pathogenesis of various diseases, notably including neurodegenerative conditions. We are using mice bearing specific germ line mutations to study the pathogenesis of (it CNS disease induced by human foamy virus (HFV), and (ii) transmissible spongiform encephalopathies. Foamy viruses are retroviruses which provoke characteristic cytopathic effects in cultured cells. Like HTLV and HIV, foamy viruses are complex viruses encoding a number of ancillary genes including a transcriptional transactivator. We have explored the pathogenic properties of HFV in transgenic mice systems. HFV transgenes encompassing the 3'-bel region exhibit a striking neurotropism. They are transcribed in a biphasic pattern during development and adulthood, and the adult phase of expression is associated with a progressive degenerative disease of the central nervous system and of striated muscle. These findings provide the first evidence of a pathology induced by HFV gene expression in a mammalian host and suggest that HFV might also act as a human pathogen. Neuron-specific expression is dependent on an internal promoter located within the env gene. HFV is capable of trans-activating HIV in double transgenic mice using an NF-kB dependent pathway, and HFV transgenic mice develop accumulations of syncytial giant cells in their brains similar to those of patients with HIV-associated encephalopathy. Spongiform encephalopathies are transmissible neurodegenerative diseases caused by an unconventional, still enigmatic, agent. Scrapie, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease belong to this group. Prusiner proposed that this infectious agent consists of an atypical protein called prion, or PrP sc, an isoform of a normal cellular protein called PrP c. A popular model for priori propagation hypothesizes PrP sccatalyzed conformational conversion of PrP c into PrP s~. In agreement with this model, mice with a homozygous deletion of the prion gene (prn-p -/-mice) are resistant to scrapie and do not propagate the infectivity. The mechanism leading to neurodegeneration in scrapie is unknown. To test whether PrP sc has a direct neurotoxic effect in the absence of PrP r we introduced a source continuously producing PrP sc into the brain of prn-p 4-mice by grafting prpS~ embryonic neural tissue to the brain of adult pro-p-/ mice. The donor tissue is derived from transgenic mice overexpressing PrP c, which develop the disease very rapidly after infection. Previous experiments have shown that grafted embryonic brain tissue differentiates into mature glial and neuronal elements. Reconstitution of a PrP-expressing graft allows us (1) to study the effect of PrP sc on surrounding .,resistant" neurons and g/ia cells, (2) to trace spread and distribution of infectious material from the grafts and (3) to examine infected tissue at time points exceeding the life span of infected mice. Our
